TRL Stock Overview
Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DaVita Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$159.70 |
| 52 Week High | US$159.70 |
| 52 Week Low | US$90.00 |
| Beta | 0.89 |
| 11 Month Change | 7.61% |
| 3 Month Change | 15.81% |
| 1 Year Change | 75.49% |
| 33 Year Change | 82.60% |
| 5 Year Change | 145.47% |
| Change since IPO | 561.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRL | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 5.5% | 1.8% | 0.8% |
| 1Y | 75.5% | 17.4% | 9.1% |
Return vs Industry: TRL exceeded the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: TRL exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| TRL volatility | |
|---|---|
| TRL Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TRL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TRL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 70,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Inc. Fundamentals Summary
| TRL fundamental statistics | |
|---|---|
| Market cap | €12.95b |
| Earnings (TTM) | €790.02m |
| Revenue (TTM) | €12.09b |
16.4x
P/E Ratio1.1x
P/S RatioIs TRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRL income statement (TTM) | |
|---|---|
| Revenue | US$12.67b |
| Cost of Revenue | US$8.51b |
| Gross Profit | US$4.16b |
| Other Expenses | US$3.33b |
| Earnings | US$827.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.09 |
| Gross Margin | 32.80% |
| Net Profit Margin | 6.53% |
| Debt/Equity Ratio | 419.9% |
How did TRL perform over the long term?
See historical performance and comparison